Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, this ...
BD (Becton, Dickinson and Company) announced European CE Mark approval for the Liverty transjugular intrahepatic portosystemic sh ...
Background Neutrophils guarantee a prompt and robust host response to pathogens. Yet, overshooting neutrophil activation ...
BDX seeks CE Mark for its Liverty TIPS Stent Graft, a next-gen device aimed at improving portal hypertension treatment and ...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced application of ...
Antivirals given for chronic hepatitis B include nucleos(t)ide analog monotherapy and pegylated interferon-alpha therapy, but ...
EADaily, . Scientists have developed a new drug for the treatment of hypertension that can effectively reduce blood pressure ...
The Company will present new NAVIGATE trial analyses at EASL 2026 (May 27–30, 2026), including an oral presentation on reduced varices based on favorable changes in markers of fibrosis formation and ...
A new review highlights how combining multiple ultrasound techniques may help detect and assess portal hypertension in liver cirrhosis BERN, CANTON OF BERN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results